{
  "conversation_id": "ffd22edf77983e200a71c609b82a587776a0296a33cead4062b8792d3da3145e",
  "chat_history": "{\n  \"messages\": [\n    {\n      \"metadata\": {},\n      \"content_type\": \"message\",\n      \"role\": \"user\",\n      \"items\": [\n        {\n          \"metadata\": {},\n          \"content_type\": \"text\",\n          \"text\": \"Retrieve the list of all clinical trials this patient is eligible for.\"\n        }\n      ]\n    },\n    {\n      \"ai_model_id\": \"gpt-5\",\n      \"metadata\": {\n        \"logprobs\": null,\n        \"id\": \"chatcmpl-C9Zf0365uX1W9ZglJ2YWRyvtSYHur\",\n        \"created\": 1756398066,\n        \"system_fingerprint\": null,\n        \"usage\": {\n          \"prompt_tokens\": 883,\n          \"completion_tokens\": 1652\n        }\n      },\n      \"content_type\": \"message\",\n      \"role\": \"assistant\",\n      \"name\": \"Orchestrator\",\n      \"items\": [\n        {\n          \"metadata\": {},\n          \"content_type\": \"text\",\n          \"text\": \"I\u2019m the Orchestrator. I will coordinate the agents to retrieve the list of clinical trials this patient is eligible for. Here\u2019s the plan and order of participants:\\n\\n- Step 1: ClinicalTrials \u2014 I will first ask ClinicalTrials what specific information they need to determine eligibility, so we only gather what\u2019s necessary. Each agent, after completing their task, should yield the chat back to me by saying \u201cback to you: Orchestrator.\u201d\\n- Step 2: PatientStatus \u2014 I will then ask PatientStatus to confirm the exact data elements they require to build a complete patient status summary (which ClinicalTrials will use). Each agent must say \u201cback to you: Orchestrator\u201d after responding.\\n- Step 3: PatientHistory \u2014 With your patient ID, I\u2019ll ask PatientHistory to retrieve the patient\u2019s timeline and all relevant details (age, staging, primary site, histology, biomarkers, prior treatments, ECOG). Each agent must say \u201cback to you: Orchestrator\u201d after responding.\\n- Step 4: PatientStatus \u2014 I will provide those details to PatientStatus to produce the current patient status. Each agent must say \u201cback to you: Orchestrator\u201d after responding.\\n- Step 5: ClinicalTrials \u2014 I will provide the finalized patient status to ClinicalTrials to retrieve the list of eligible clinical trials. Each agent must say \u201cback to you: Orchestrator\u201d after responding.\\n\\nOptional: If trial matching would benefit from location/travel preferences, I can collect that from you as well to refine the list.\\n\\nUser, can you provide me with the patient\u2019s ID? If available, please also share the patient\u2019s location (city/state or country) and travel radius preferences to help narrow trial options.\\n\\nPlease confirm this plan, and I\u2019ll proceed.\"\n        }\n      ],\n      \"finish_reason\": \"stop\"\n    },\n    {\n      \"metadata\": {},\n      \"content_type\": \"message\",\n      \"role\": \"user\",\n      \"items\": [\n        {\n          \"metadata\": {},\n          \"content_type\": \"text\",\n          \"text\": \"ClinicalTrials: Please confirm the minimum data elements you require to assess eligibility for patient-level trial matching. Provide an explicit list of fields and any accepted value sets or formats, and include a structured template (JSON preferred) we can populate. Also indicate which fields are mandatory vs optional and any tolerances (e.g., ranges, unknown/NA allowed). Specifically, please clarify needs for:\\n\\n- Disease characterization: primary tumor site, histology/subtype, stage (AJCC/FIGO/etc.), sites of disease, measurable disease per RECIST (yes/no).\\n- Molecular/biomarkers: specific genes/alterations (e.g., EGFR, ALK, BRAF, MSI/MMR, PD-L1, TMB), fusion partners, variant classes, copy number thresholds, IHC scores, FISH cutoffs, assay requirements, sample recency.\\n- Treatment history: prior systemic regimens with lines and dates, prior targeted/immunotherapy exposure, prior radiation/surgery, prior transplant/CAR-T, prior trial participation, refractory/relapsed status, washout periods.\\n- Performance/functional status: ECOG or Karnofsky, weight/BMI if dosing constraints apply.\\n- Organ function and key labs (with thresholds you use): ANC, platelets, hemoglobin, creatinine/CrCl, AST/ALT, bilirubin, albumin, INR/PTT, QTc, LVEF (if relevant).\\n- Comorbidities/exclusions: CNS metastases and status (treated/untreated, symptomatic), seizures, autoimmune disease, active infections (HBV/HCV/HIV) and viral loads/serologies, interstitial lung disease/pneumonitis, bleeding risk/anticoagulation, cardiac arrhythmias, uncontrolled hypertension, pregnancy/lactation, fertility/contraception requirements.\\n- Concomitant meds and restrictions: strong CYP inducers/inhibitors, steroids, QT-prolonging agents, immunosuppression.\\n- Demographics: age, sex, reproductive potential, race/ethnicity if needed for specific trials, smoking status (if relevant).\\n- Logistics: patient location (city/state/country), maximum travel radius, tele-trial/home phlebotomy acceptance, language needs.\\n- Timing constraints: days since last therapy/surgery/radiation, steroid use timelines, washouts for biologics/IO/RT, wound healing windows.\\n- Additional requirements: archival vs fresh biopsy availability, consent capacity, tissue/ctDNA availability, imaging frequency tolerance.\\n\\nIf you have a preferred schema, please provide it. If not, I propose a compact JSON structure capturing these elements. Also confirm whether you can filter by geography (e.g., by state) so we can later address: \u201cWhich clinical trials are recruiting patients in California?\u201d\\n\\nPlease respond with the precise field list, accepted values/ranges, and any examples, then say \u201cback to you: Orchestrator.\u201d\"\n        }\n      ]\n    },\n    {\n      \"ai_model_id\": \"gpt-5\",\n      \"metadata\": {\n        \"logprobs\": null,\n        \"id\": \"chatcmpl-C9ZfoPbll9AYBCd7Ce85EpYjEPciZ\",\n        \"created\": 1756398116,\n        \"system_fingerprint\": null,\n        \"usage\": {\n          \"prompt_tokens\": 1847,\n          \"completion_tokens\": 6456\n        }\n      },\n      \"content_type\": \"message\",\n      \"role\": \"assistant\",\n      \"name\": \"ClinicalTrials\",\n      \"items\": [\n        {\n          \"metadata\": {},\n          \"content_type\": \"text\",\n          \"text\": \"Below is the minimum data we need to run algorithmic trial matching, followed by a fuller schema you can use to maximize match precision. I\u2019ve listed accepted values/formats, tolerances, and which fields are mandatory vs optional. A compact, ready-to-populate JSON template is included at the end, along with a \u201crequired_minimum_for_matching\u201d list.\\n\\nCore mandatory fields for initial automated matching (must be provided)\\n- Demographics:\\n  - age: integer in years (e.g., 63)\\n- Disease characterization:\\n  - primary_site: free text or ICD-O topography (e.g., \u201clung\u201d, \u201cC34.9\u201d)\\n  - histology: free text or ICD-O-3/WHO (e.g., \u201cadenocarcinoma\u201d, \u201c8140/3\u201d)\\n  - stage: AJCC/FIGO/etc. string (e.g., \u201cAJCC 8th IVB\u201d, \u201cFIGO IIIC1\u201d, \u201crecurrent/metastatic\u201d)\\n- Performance:\\n  - ecog: integer 0\u20134\\n- Treatment history:\\n  - first_line_treatment: regimen name(s) and dates (e.g., \u201ccarboplatin+pemetrexed+pembrolizumab\u201d, 2022-01 to 2022-07)\\n  - second_line_treatment: regimen name(s) and dates or \u201cnone\u201d\\n- Biomarkers:\\n  - biomarkers: array; if none/unknown use [] or [{\\\"gene\\\":\\\"NA\\\",\\\"status\\\":\\\"unknown\\\"}]\\n\\nStrongly recommended (increases match accuracy; many trials require these)\\n- Disease details:\\n  - measurable_disease_recist: yes/no/unknown (RECIST 1.1 default)\\n  - sites_of_disease: array (e.g., [\\\"lung\\\",\\\"liver\\\",\\\"bone\\\"])\\n- Biomarkers:\\n  - PD-L1: value with scale (TPS or CPS), assay (e.g., 22C3), and date\\n  - MSI/MMR: \u201cMSI-H\u201d, \u201cMSS\u201d, \u201cdMMR\u201d, \u201cpMMR\u201d\\n  - TMB: numeric mut/Mb, assay and date\\n  - HER2: IHC 0/1+/2+/3+; ISH/FISH ratio and/or copy number\\n  - Specific alterations: HGVS or simplified (e.g., EGFR exon 19 del, ALK fusion EML4-v1, BRAF V600E, MET exon14 skipping, KRAS G12C, NTRK fusion, RET fusion, ROS1 fusion, BRCA1/2 P/LP)\\n  - Assay metadata: source (tumor/ctDNA), vendor/platform (e.g., FoundationOne, Tempus), report date, tissue site, sample age (months)\\n- Treatment history:\\n  - all prior systemic regimens with line numbers, start/stop dates, best response (per RECIST if available), reason for discontinuation\\n  - prior IO (PD-1/PD-L1/CTLA-4), prior targeted agents by target (EGFR, ALK, HER2, KRAS G12C, PARP, VEGF/VEGFR, CDK4/6, PI3K, etc.)\\n  - prior radiation (sites, doses, dates), prior major surgeries and dates\\n  - prior cellular therapy (ASCT, allo-SCT, CAR-T), prior investigational agents or trial IDs, refractory/relapsed status\\n- Performance/functional:\\n  - Karnofsky (0\u2013100) if ECOG unavailable\\n  - weight (kg), height (cm), BMI or BSA if dosing constraints apply\\n- Organ function and key labs (most common default thresholds we apply for prescreening; individual trials vary):\\n  - ANC: \u2265 1.5 \u00d7 10^9/L (some allow \u2265 1.0)\\n  - Platelets: \u2265 100 \u00d7 10^9/L (some allow \u2265 75)\\n  - Hemoglobin: \u2265 9.0 g/dL (transfusion permitted per-protocol)\\n  - Creatinine: \u2264 1.5 \u00d7 ULN or CrCl/eGFR \u2265 50\u201360 mL/min\\n  - AST/ALT: \u2264 2.5 \u00d7 ULN (\u2264 5 \u00d7 ULN if liver mets)\\n  - Total bilirubin: \u2264 1.5 \u00d7 ULN (\u2264 3 \u00d7 ULN or per Gilbert\u2019s)\\n  - Albumin: \u2265 3.0 g/dL (phase 1 often \u2265 2.8\u20133.0)\\n  - INR/PTT: \u2264 1.5 \u00d7 ULN unless on therapeutic anticoagulation\\n  - QTc: \u2264 470 ms (men \u2264 450 ms typical); method (Fridericia/Bazett)\\n  - LVEF: \u2265 50% if cardiotoxic agents involved; echo/MUGA date\\n  - Lab recency: within 14 days typical; up to 28 days acceptable for early prescreen\\n- Comorbidities/exclusions:\\n  - CNS metastases: none/treated-stable/untreated/symptomatic; steroids dose (prednisone mg/day or equivalent), seizure control\\n  - Autoimmune disease: type, activity, systemic therapy use\\n  - Infections: HBV/HCV/HIV status; HBV DNA/HCV RNA copies; CD4 count if HIV; on antivirals? yes/no\\n  - ILD/pneumonitis history; pulmonary fibrosis\\n  - Bleeding risk/anticoagulation (warfarin/DOAC), recent major bleed\\n  - Cardiac: arrhythmias, heart failure (NYHA), MI within 6 months, uncontrolled hypertension\\n  - Metabolic: uncontrolled diabetes, significant hepatic/renal impairment\\n  - Pregnancy/lactation; reproductive potential; contraception agreement\\n- Concomitant meds/restrictions:\\n  - strong CYP3A/2D6/2C8 inhibitors/inducers; P-gp substrates; QT-prolonging agents\\n  - systemic steroids (dose and indication), immunosuppressants, herbal supplements (e.g., St. John\u2019s wort)\\n- Logistics and geography:\\n  - location: city, state/province, country; ZIP/postal code\\n  - max_travel_radius_km: integer\\n  - tele-trial/home services acceptable: yes/no\\n  - language needs and availability of caregiver/translator\\n- Timing constraints:\\n  - days since last chemotherapy, IO, targeted therapy, RT, surgery, major procedure\\n  - washouts: biologics (typically \u2265 28 days), IO (\u2265 28 days), TKIs (\u2265 5 half-lives or 7\u201314 days), RT (\u2265 7\u201314 days focal; \u2265 28 days wide-field), surgery/wound healing (\u2265 14\u201328 days)\\n  - steroid taper timeline\\n- Additional requirements:\\n  - archival_tissue_available: yes/no; blocks/slides; site/date\\n  - fresh_biopsy_feasible: yes/no; safe target lesion: yes/no\\n  - ctDNA feasible: yes/no\\n  - consent capacity and caregiver support\\n  - imaging cadence tolerance (e.g., q6\u20138 weeks)\\n\\nAccepted values and formats\\n- Dates: ISO 8601 (YYYY-MM-DD); use null if unknown\\n- Booleans: true/false; allow \\\"unknown\\\" string where indicated\\n- Enums:\\n  - ecog: 0,1,2,3,4\\n  - measurable_disease_recist: \\\"yes\\\",\\\"no\\\",\\\"unknown\\\"\\n  - msi_mmr: \\\"MSI-H\\\",\\\"MSS\\\",\\\"dMMR\\\",\\\"pMMR\\\",\\\"unknown\\\"\\n  - pd_l1_scale: \\\"TPS\\\",\\\"CPS\\\",\\\"IC\\\" (for some tumor types), or \\\"unknown\\\"\\n  - sex_at_birth: \\\"female\\\",\\\"male\\\",\\\"intersex\\\",\\\"unknown\\\"\\n  - reproductive_potential: \\\"yes\\\",\\\"no\\\",\\\"unknown\\\"\\n  - cns_status: \\\"none\\\",\\\"treated_stable\\\",\\\"untreated\\\",\\\"symptomatic\\\",\\\"unknown\\\"\\n  - infection_status: \\\"negative\\\",\\\"positive\\\",\\\"unknown\\\"\\n  - anticoagulation: \\\"none\\\",\\\"prophylactic\\\",\\\"therapeutic\\\"\\n  - assay_source: \\\"tumor\\\",\\\"ctDNA\\\",\\\"other\\\"\\n  - stage_system: \\\"AJCC\\\",\\\"FIGO\\\",\\\"AnnArbor\\\",\\\"DurieSalmon\\\",\\\"Rai\\\",\\\"Other\\\"\\n- Units:\\n  - labs in conventional units noted above; if SI units used, include units explicitly\\n- Tolerances for unknown/NA:\\n  - For initial matching, unknown is acceptable for most recommended fields; mandatory fields listed above must be provided\\n  - We apply conservative filters when values are unknown (e.g., may exclude QTc-restricted trials if QTc unknown)\\n\\nGeography filtering\\n- Yes. We can filter by country, state/province, city, ZIP/postal-code radius, or by specific site names. Example: \u201cUnited States, California\u201d or ZIP radius \u201c94103 + 100 miles\u201d. If you later ask \u201cWhich trials are recruiting patients in California?\u201d, we can restrict to that geography.\\n\\nCompact JSON template (populate and return). Include null or \\\"unknown\\\" where appropriate.\\n\\n{\\n  \\\"demographics\\\": {\\n    \\\"age\\\": 63,\\n    \\\"sex_at_birth\\\": \\\"female\\\",\\n    \\\"gender_identity\\\": \\\"female\\\",\\n    \\\"reproductive_potential\\\": \\\"no\\\",\\n    \\\"race\\\": \\\"optional\\\",\\n    \\\"ethnicity\\\": \\\"optional\\\",\\n    \\\"smoking_status\\\": \\\"never/former/current/unknown\\\"\\n  },\\n  \\\"disease\\\": {\\n    \\\"primary_site\\\": \\\"lung\\\",\\n    \\\"histology\\\": \\\"adenocarcinoma\\\",\\n    \\\"icdo_topography\\\": \\\"C34.9\\\",\\n    \\\"icdo_morphology\\\": \\\"8140/3\\\",\\n    \\\"stage_system\\\": \\\"AJCC\\\",\\n    \\\"stage\\\": \\\"IVB\\\",\\n    \\\"measurable_disease_recist\\\": \\\"yes\\\",\\n    \\\"sites_of_disease\\\": [\\\"lung\\\",\\\"liver\\\"],\\n    \\\"diagnosis_date\\\": \\\"2022-01-15\\\"\\n  },\\n  \\\"biomarkers\\\": [\\n    {\\n      \\\"gene\\\": \\\"EGFR\\\",\\n      \\\"alteration\\\": \\\"exon19del\\\",\\n      \\\"variant_hgvs_c\\\": \\\"c.2235_2249del\\\",\\n      \\\"variant_hgvs_p\\\": \\\"p.E746_A750del\\\",\\n      \\\"variant_class\\\": \\\"SNV/indel/fusion/amp\\\",\\n      \\\"copy_number\\\": null,\\n      \\\"fusion_partner\\\": null,\\n      \\\"assay_source\\\": \\\"tumor\\\",\\n      \\\"assay_vendor\\\": \\\"FoundationOne CDx\\\",\\n      \\\"report_date\\\": \\\"2022-02-01\\\",\\n      \\\"tissue_site\\\": \\\"lung\\\",\\n      \\\"sample_recency_months\\\": 6\\n    },\\n    {\\n      \\\"gene\\\": \\\"PD-L1\\\",\\n      \\\"pd_l1_value\\\": 60,\\n      \\\"pd_l1_scale\\\": \\\"TPS\\\",\\n      \\\"assay_vendor\\\": \\\"22C3 pharmDx\\\",\\n      \\\"report_date\\\": \\\"2022-02-01\\\"\\n    },\\n    {\\n      \\\"gene\\\": \\\"MSI\\\",\\n      \\\"msi_mmr\\\": \\\"MSS\\\",\\n      \\\"assay_vendor\\\": \\\"Tempus xT\\\",\\n      \\\"report_date\\\": \\\"2022-02-01\\\"\\n    },\\n    {\\n      \\\"gene\\\": \\\"TMB\\\",\\n      \\\"tmb_value_mut_per_mb\\\": 5.2,\\n      \\\"assay_vendor\\\": \\\"Tempus xT\\\",\\n      \\\"report_date\\\": \\\"2022-02-01\\\"\\n    },\\n    {\\n      \\\"gene\\\": \\\"ERBB2\\\",\\n      \\\"ihc_score\\\": \\\"0/1+/2+/3+\\\",\\n      \\\"fish_ratio\\\": null,\\n      \\\"copy_number\\\": null,\\n      \\\"assay_vendor\\\": \\\"IHC/FISH\\\",\\n      \\\"report_date\\\": \\\"2022-02-01\\\"\\n    }\\n  ],\\n  \\\"treatment_history\\\": {\\n    \\\"first_line_treatment\\\": {\\n      \\\"regimen\\\": \\\"carboplatin+pemetrexed+pembrolizumab\\\",\\n      \\\"start_date\\\": \\\"2022-02-15\\\",\\n      \\\"end_date\\\": \\\"2022-07-30\\\",\\n      \\\"best_response\\\": \\\"PR\\\",\\n      \\\"reason_for_stop\\\": \\\"progression\\\"\\n    },\\n    \\\"second_line_treatment\\\": {\\n      \\\"regimen\\\": \\\"osimertinib\\\",\\n      \\\"start_date\\\": \\\"2022-08-10\\\",\\n      \\\"end_date\\\": \\\"2023-05-15\\\",\\n      \\\"best_response\\\": \\\"SD\\\",\\n      \\\"reason_for_stop\\\": \\\"progression\\\"\\n    },\\n    \\\"systemic_regimens\\\": [\\n      {\\n        \\\"line_number\\\": 1,\\n        \\\"regimen\\\": \\\"carboplatin+pemetrexed+pembrolizumab\\\",\\n        \\\"start_date\\\": \\\"2022-02-15\\\",\\n        \\\"end_date\\\": \\\"2022-07-30\\\",\\n        \\\"best_response\\\": \\\"PR\\\"\\n      },\\n      {\\n        \\\"line_number\\\": 2,\\n        \\\"regimen\\\": \\\"osimertinib\\\",\\n        \\\"start_date\\\": \\\"2022-08-10\\\",\\n        \\\"end_date\\\": \\\"2023-05-15\\\",\\n        \\\"best_response\\\": \\\"SD\\\"\\n      }\\n    ],\\n    \\\"radiation\\\": [\\n      { \\\"site\\\": \\\"thoracic\\\", \\\"dose_gy\\\": 30, \\\"fractions\\\": 10, \\\"end_date\\\": \\\"2022-12-01\\\" }\\n    ],\\n    \\\"surgery\\\": [\\n      { \\\"procedure\\\": \\\"lung wedge resection\\\", \\\"date\\\": \\\"2022-01-20\\\" }\\n    ],\\n    \\\"cellular_therapy\\\": {\\n      \\\"transplant\\\": null,\\n      \\\"car_t\\\": null\\n    },\\n    \\\"trial_participation\\\": [\\n      { \\\"trial_id\\\": \\\"NCT01234567\\\", \\\"start_date\\\": \\\"2023-06-01\\\", \\\"end_date\\\": \\\"2023-10-01\\\", \\\"agent\\\": \\\"investigational EGFR TKI\\\" }\\n    ],\\n    \\\"refractory_relapsed_status\\\": \\\"relapsed/refractory/na\\\"\\n  },\\n  \\\"performance_status\\\": {\\n    \\\"ecog\\\": 1,\\n    \\\"karnofsky\\\": 80,\\n    \\\"weight_kg\\\": 68.5,\\n    \\\"height_cm\\\": 165,\\n    \\\"bmi\\\": 25.2\\n  },\\n  \\\"labs\\\": {\\n    \\\"collection_date\\\": \\\"2024-04-01\\\",\\n    \\\"anc_10e9_per_L\\\": 2.1,\\n    \\\"platelets_10e9_per_L\\\": 180,\\n    \\\"hemoglobin_g_per_dL\\\": 10.2,\\n    \\\"creatinine_mg_per_dL\\\": 0.9,\\n    \\\"creatinine_clearance_mL_per_min\\\": 70,\\n    \\\"ast_u_per_L\\\": 32,\\n    \\\"alt_u_per_L\\\": 28,\\n    \\\"total_bilirubin_mg_per_dL\\\": 0.8,\\n    \\\"albumin_g_per_dL\\\": 3.6,\\n    \\\"inr\\\": 1.1,\\n    \\\"ptt_seconds\\\": 30,\\n    \\\"qtc_ms\\\": 440,\\n    \\\"qtc_method\\\": \\\"Fridericia\\\",\\n    \\\"lvef_percent\\\": 60\\n  },\\n  \\\"comorbidities\\\": {\\n    \\\"cns_status\\\": \\\"treated_stable\\\",\\n    \\\"on_cns_steroids_prednisone_mg_per_day\\\": 5,\\n    \\\"seizure_controlled\\\": true,\\n    \\\"autoimmune_disease\\\": [{ \\\"condition\\\": \\\"psoriasis\\\", \\\"on_systemic_immunosuppression\\\": false }],\\n    \\\"infections\\\": {\\n      \\\"hbv_status\\\": \\\"negative\\\",\\n      \\\"hbv_dna_iu_per_mL\\\": null,\\n      \\\"hcv_status\\\": \\\"negative\\\",\\n      \\\"hcv_rna_iu_per_mL\\\": null,\\n      \\\"hiv_status\\\": \\\"negative\\\",\\n      \\\"cd4_count_per_uL\\\": null,\\n      \\\"on_antivirals\\\": false\\n    },\\n    \\\"ild_pneumonitis_history\\\": false,\\n    \\\"bleeding_risk\\\": \\\"none\\\",\\n    \\\"anticoagulation\\\": \\\"none\\\",\\n    \\\"cardiac_arrhythmia\\\": false,\\n    \\\"heart_failure_nyha\\\": null,\\n    \\\"uncontrolled_hypertension\\\": false,\\n    \\\"diabetes_uncontrolled\\\": false,\\n    \\\"pregnant\\\": false,\\n    \\\"lactating\\\": false,\\n    \\\"contraception_agreement\\\": true\\n  },\\n  \\\"concomitant_meds\\\": {\\n    \\\"cyp3a_inhibitors\\\": [],\\n    \\\"cyp3a_inducers\\\": [],\\n    \\\"qtc_prolonging_agents\\\": [],\\n    \\\"anticoagulants\\\": [],\\n    \\\"systemic_steroids_mg_pred_eq_per_day\\\": 0,\\n    \\\"immunosuppressants\\\": [],\\n    \\\"herbals\\\": []\\n  },\\n  \\\"logistics\\\": {\\n    \\\"location_city\\\": \\\"San Francisco\\\",\\n    \\\"location_state\\\": \\\"CA\\\",\\n    \\\"location_country\\\": \\\"USA\\\",\\n    \\\"postal_code\\\": \\\"94103\\\",\\n    \\\"max_travel_radius_km\\\": 160,\\n    \\\"teletrial_ok\\\": true,\\n    \\\"language_needs\\\": \\\"English\\\"\\n  },\\n  \\\"timing\\\": {\\n    \\\"last_chemo_date\\\": \\\"2024-03-10\\\",\\n    \\\"last_io_date\\\": \\\"2023-05-15\\\",\\n    \\\"last_tki_date\\\": \\\"2023-05-15\\\",\\n    \\\"last_radiation_end_date\\\": \\\"2022-12-01\\\",\\n    \\\"last_major_surgery_date\\\": \\\"2022-01-20\\\",\\n    \\\"steroid_taper_end_date\\\": \\\"2023-02-01\\\"\\n  },\\n  \\\"additional_requirements\\\": {\\n    \\\"archival_tissue_available\\\": true,\\n    \\\"archival_tissue_details\\\": \\\"FFPE block, lung primary, 2022-01\\\",\\n    \\\"fresh_biopsy_feasible\\\": true,\\n    \\\"safe_target_lesion_for_biopsy\\\": true,\\n    \\\"ctdna_feasible\\\": true,\\n    \\\"consent_capacity\\\": true,\\n    \\\"imaging_cadence_tolerance_weeks\\\": 8\\n  },\\n  \\\"required_minimum_for_matching\\\": [\\n    \\\"demographics.age\\\",\\n    \\\"disease.primary_site\\\",\\n    \\\"disease.histology\\\",\\n    \\\"disease.stage\\\",\\n    \\\"performance_status.ecog\\\",\\n    \\\"treatment_history.first_line_treatment\\\",\\n    \\\"treatment_history.second_line_treatment\\\",\\n    \\\"biomarkers\\\"\\n  ]\\n}\\n\\nNotes\\n- If a field is not applicable or unknown, use null or \\\"unknown\\\" as shown. For initial matching, we must have every item in required_minimum_for_matching.\\n- Lab thresholds are prescreen defaults and may be relaxed or tightened per protocol; if your labs don\u2019t meet these, we will still return trials whose criteria you meet.\\n- We can incorporate tumor-specific required biomarkers (e.g., EGFR/ALK for NSCLC, IDH1/2 for glioma, BRAF for melanoma/CRC) if you annotate \u201cmust_have\u201d markers; otherwise we infer from disease context.\\n\\nIf you prefer a formal JSON Schema with required lists and type constraints, I can provide Draft-07 on request.\\n\\nback to you: Orchestrator.\"\n        }\n      ],\n      \"finish_reason\": \"stop\"\n    },\n    {\n      \"ai_model_id\": \"gpt-5\",\n      \"metadata\": {\n        \"logprobs\": null,\n        \"id\": \"chatcmpl-C9Zh92kdMqF4XKS0EK9h2Qzwjn7ON\",\n        \"created\": 1756398199,\n        \"system_fingerprint\": null,\n        \"usage\": {\n          \"prompt_tokens\": 9898,\n          \"completion_tokens\": 1571\n        }\n      },\n      \"content_type\": \"message\",\n      \"role\": \"assistant\",\n      \"name\": \"Orchestrator\",\n      \"items\": [\n        {\n          \"metadata\": {},\n          \"content_type\": \"text\",\n          \"text\": \"I\u2019m the Orchestrator. We\u2019ve received ClinicalTrials\u2019 required data schema and template. Here\u2019s the plan and order to move forward to retrieve eligible clinical trials for this patient:\\n\\n- Step 2: PatientStatus \u2014 I will ask PatientStatus to confirm the exact fields, formats, and tolerances they require to build the patient status summary that ClinicalTrials will use. Each agent must yield the chat back to me by saying \u201cback to you: Orchestrator.\u201d\\n- Step 3: PatientHistory \u2014 Once you provide the patient ID, I will ask PatientHistory to retrieve all required elements (age, primary site, histology, stage, biomarkers, treatment history, ECOG, and any additional details needed by PatientStatus/ClinicalTrials). Each agent must say \u201cback to you: Orchestrator.\u201d\\n- Step 4: PatientStatus \u2014 I will provide the retrieved data to PatientStatus to produce the current patient status object in the agreed JSON format. Each agent must say \u201cback to you: Orchestrator.\u201d\\n- Step 5: ClinicalTrials \u2014 I will then pass the finalized patient status to ClinicalTrials to generate the list of eligible trials, optionally filtered by geography and logistics. Each agent must say \u201cback to you: Orchestrator.\u201d\\n\\nPatientStatus, proceed with:\\n- Confirm your minimal mandatory fields to construct the \u201cpatient status\u201d artifact for trial matching, your accepted value sets/formats, and tolerances for unknown/NA.\\n- Provide a concise JSON template aligned to ClinicalTrials\u2019 required_minimum_for_matching (age, primary_site, histology, stage, ECOG, first_line_treatment, second_line_treatment, biomarkers), plus any additional fields you strongly recommend (e.g., measurable disease, sites of disease, key labs, comorbidities) and their formats.\\n- Indicate any recency requirements (e.g., labs within X days), and default handling if multiple conflicting values are present.\\n- Confirm you can ingest ICD-O topography/morphology or free text for disease characterization and how you prefer staging (system + value).\\n\\nPlease end your response with \u201cback to you: Orchestrator.\u201d\\n\\nUser, can you provide me with the patient\u2019s ID so I can pull the chart via PatientHistory? Additionally, please share:\\n- Patient\u2019s location (city/state/country) and maximum travel radius (km or miles) for site filtering\\n- Any logistics preferences (tele-trial/home services acceptable: yes/no; language needs)\\n- Optional: any immediate exclusions we should consider (e.g., unwilling to undergo biopsy, no blood transfusions)\\n\\nOnce you confirm, I\u2019ll proceed with Steps 3\u20135.\"\n        }\n      ],\n      \"finish_reason\": \"stop\"\n    },\n    {\n      \"metadata\": {},\n      \"content_type\": \"message\",\n      \"role\": \"user\",\n      \"items\": [\n        {\n          \"metadata\": {},\n          \"content_type\": \"text\",\n          \"text\": \"PatientStatus: Please confirm the following to enable construction of a patient status artifact compatible with ClinicalTrials\u2019 matching schema:\\n\\n1) Minimal mandatory fields you require, with accepted values/formats and tolerances for unknown:\\n- Demographics: age (integer years)\\n- Disease characterization: primary_site (free text or ICD-O topography), histology (free text or ICD-O-3/WHO), stage (system + value; e.g., \u201cAJCC 8th IVB\u201d or system: AJCC, stage: IVB)\\n- Performance: ECOG (0\u20134)\\n- Treatment history: first_line_treatment (regimen, start/end dates), second_line_treatment (regimen/dates or \u201cnone\u201d)\\n- Biomarkers: array; allow [] or [{\\\"gene\\\":\\\"NA\\\",\\\"status\\\":\\\"unknown\\\"}] if unknown\\nPlease list any additional \u201cmust-haves\u201d from your perspective beyond ClinicalTrials\u2019 required_minimum_for_matching.\\n\\n2) Provide a concise JSON template aligned to ClinicalTrials\u2019 required_minimum_for_matching, plus any strongly recommended fields you use to enhance precision (e.g., measurable_disease_recist, sites_of_disease, key labs with thresholds, CNS status, infections, organ function, comorbidities). For each added field, include accepted value sets (enums), formats (ISO 8601 dates, units), and whether null/unknown is acceptable.\\n\\n3) Recency requirements:\\n- Specify freshness windows you apply (e.g., labs within 14\u201328 days, imaging within 6\u20138 weeks, echo/QTc within X months).\\n- State how you handle multiple or conflicting values (e.g., prefer most recent; tie-break on higher data quality/source; conservative default if discordant).\\n\\n4) Coding flexibility:\\n- Confirm you can ingest disease characterization as ICD-O topography/morphology or free text.\\n- Indicate your preferred staging representation: do you want \u201cstage_system\u201d + \u201cstage_value\u201d fields (e.g., \\\"AJCC\\\" + \\\"IVB\\\") or a single composite string?\\n- Note any tumor-type-specific fields you auto-infer (e.g., EGFR/ALK for NSCLC) versus those you require explicitly.\\n\\nPlease end your response with \u201cback to you: Orchestrator.\u201d\"\n        }\n      ]\n    },\n    {\n      \"ai_model_id\": \"gpt-5\",\n      \"metadata\": {\n        \"logprobs\": null,\n        \"id\": \"chatcmpl-C9Zi8QVANYgTpQcifWLKPFqpZhbKz\",\n        \"created\": 1756398260,\n        \"system_fingerprint\": null,\n        \"usage\": {\n          \"prompt_tokens\": 10196,\n          \"completion_tokens\": 4516\n        }\n      },\n      \"content_type\": \"message\",\n      \"role\": \"assistant\",\n      \"name\": \"PatientStatus\",\n      \"items\": [\n        {\n          \"metadata\": {},\n          \"content_type\": \"text\",\n          \"text\": \"PatientStatus here. Confirming requirements and providing a concise, interoperable template aligned to ClinicalTrials\u2019 schema.\\n\\n1) Minimal mandatory fields I require (for a complete PatientStatus artifact used in trial matching), with accepted values and tolerances\\n- Demographics\\n  - age: integer years, 0\u2013120; required; unknown not allowed for matching\\n  - patient_gender (aka sex_at_birth): \\\"female\\\",\\\"male\\\",\\\"intersex\\\",\\\"unknown\\\"; required by PatientStatus; unknown allowed but may limit certain matches\\n- Disease characterization\\n  - primary_site: free text or ICD-O topography (e.g., \\\"lung\\\" or \\\"C34.9\\\"); required; unknown not allowed\\n  - histology: free text or ICD-O-3/WHO (e.g., \\\"adenocarcinoma\\\" or \\\"8140/3\\\"); required; unknown not allowed\\n  - stage: provide either composite string (e.g., \\\"AJCC 8th IVB\\\") or structured fields stage_system + stage_value; required; unknown not allowed\\n    - stage_system: \\\"AJCC\\\",\\\"FIGO\\\",\\\"AnnArbor\\\",\\\"DurieSalmon\\\",\\\"Rai\\\",\\\"Other\\\"\\n    - stage_value: free text (e.g., \\\"IVB\\\",\\\"recurrent/metastatic\\\")\\n- Performance\\n  - ecog: integer 0\u20134; required; unknown not allowed\\n- Treatment history\\n  - first_line_treatment: required; unknown not allowed\\n    - regimen: free text (e.g., \\\"carboplatin+pemetrexed+pembrolizumab\\\")\\n    - start_date, end_date: ISO 8601 (YYYY-MM-DD); end_date may be null if ongoing\\n  - second_line_treatment: required; may be {\\\"regimen\\\":\\\"none\\\"} if none given\\n    - same fields as above; or \\\"none\\\"\\n- Biomarkers\\n  - biomarkers: array of objects; required; allow [] or [{\\\"gene\\\":\\\"NA\\\",\\\"status\\\":\\\"unknown\\\"}] if unknown\\n  - Accepted formats include gene/alteration or clinical assays (PD-L1, MSI/MMR, TMB, HER2, fusions, copy number), with assay metadata when available\\n\\nAdditional PatientStatus \u201cmust-haves\u201d beyond ClinicalTrials\u2019 required_minimum_for_matching\\n- patient_gender (sex_at_birth) as above. All other additions below are strongly recommended but not strict must-haves.\\n\\n2) Concise JSON template (aligned to ClinicalTrials\u2019 minimum, plus strongly recommended fields)\\nNotes:\\n- Dates ISO 8601. Booleans true/false. Use null or \\\"unknown\\\" where indicated.\\n- Enums shown below template.\\n\\n{\\n  \\\"demographics\\\": {\\n    \\\"age\\\": null,\\n    \\\"patient_gender\\\": \\\"female/male/intersex/unknown\\\",\\n    \\\"reproductive_potential\\\": \\\"yes/no/unknown\\\"\\n  },\\n  \\\"disease\\\": {\\n    \\\"primary_site\\\": null,\\n    \\\"histology\\\": null,\\n    \\\"stage_system\\\": \\\"AJCC/FIGO/AnnArbor/DurieSalmon/Rai/Other\\\",\\n    \\\"stage_value\\\": \\\"e.g., IVB or recurrent/metastatic\\\",\\n    \\\"stage_composite\\\": \\\"optional e.g., 'AJCC 8th IVB'\\\",\\n    \\\"measurable_disease_recist\\\": \\\"yes/no/unknown\\\",\\n    \\\"sites_of_disease\\\": [\\\"optional e.g., lung\\\",\\\"liver\\\",\\\"bone\\\"],\\n    \\\"diagnosis_date\\\": \\\"YYYY-MM-DD or null\\\"\\n  },\\n  \\\"biomarkers\\\": [\\n    {\\n      \\\"gene\\\": \\\"e.g., EGFR/ALK/BRCA1/PD-L1/MSI/TMB/HER2\\\",\\n      \\\"alteration\\\": \\\"e.g., exon19del, V600E, fusion, amp; or 'NA'\\\",\\n      \\\"variant_hgvs_c\\\": \\\"optional\\\",\\n      \\\"variant_hgvs_p\\\": \\\"optional\\\",\\n      \\\"variant_class\\\": \\\"SNV/indel/fusion/amp/loh/ihc/fish/other/unknown\\\",\\n      \\\"copy_number\\\": null,\\n      \\\"fusion_partner\\\": \\\"optional\\\",\\n      \\\"pd_l1_value\\\": null,\\n      \\\"pd_l1_scale\\\": \\\"TPS/CPS/IC/unknown\\\",\\n      \\\"msi_mmr\\\": \\\"MSI-H/MSS/dMMR/pMMR/unknown\\\",\\n      \\\"tmb_value_mut_per_mb\\\": null,\\n      \\\"ihc_score\\\": \\\"0/1+/2+/3+\\\",\\n      \\\"fish_ratio\\\": null,\\n      \\\"assay_source\\\": \\\"tumor/ctDNA/other/unknown\\\",\\n      \\\"assay_vendor\\\": \\\"optional\\\",\\n      \\\"report_date\\\": \\\"YYYY-MM-DD or null\\\",\\n      \\\"tissue_site\\\": \\\"optional\\\",\\n      \\\"sample_recency_months\\\": null\\n    }\\n  ],\\n  \\\"treatment_history\\\": {\\n    \\\"first_line_treatment\\\": {\\n      \\\"regimen\\\": null,\\n      \\\"start_date\\\": null,\\n      \\\"end_date\\\": null,\\n      \\\"best_response\\\": \\\"CR/PR/SD/PD/NE/unknown\\\",\\n      \\\"reason_for_stop\\\": \\\"progression/toxicity/completed/other/unknown\\\"\\n    },\\n    \\\"second_line_treatment\\\": {\\n      \\\"regimen\\\": \\\"none or regimen string\\\",\\n      \\\"start_date\\\": null,\\n      \\\"end_date\\\": null,\\n      \\\"best_response\\\": \\\"CR/PR/SD/PD/NE/unknown\\\",\\n      \\\"reason_for_stop\\\": \\\"progression/toxicity/completed/other/unknown\\\"\\n    },\\n    \\\"systemic_regimens\\\": [\\n      {\\n        \\\"line_number\\\": 1,\\n        \\\"regimen\\\": \\\"optional\\\",\\n        \\\"start_date\\\": \\\"YYYY-MM-DD\\\",\\n        \\\"end_date\\\": \\\"YYYY-MM-DD or null\\\",\\n        \\\"best_response\\\": \\\"CR/PR/SD/PD/NE/unknown\\\"\\n      }\\n    ],\\n    \\\"radiation\\\": [\\n      { \\\"site\\\": \\\"optional\\\", \\\"dose_gy\\\": null, \\\"fractions\\\": null, \\\"end_date\\\": \\\"YYYY-MM-DD or null\\\" }\\n    ],\\n    \\\"surgery\\\": [\\n      { \\\"procedure\\\": \\\"optional\\\", \\\"date\\\": \\\"YYYY-MM-DD or null\\\" }\\n    ],\\n    \\\"trial_participation\\\": [\\n      { \\\"trial_id\\\": \\\"optional\\\", \\\"agent\\\": \\\"optional\\\", \\\"start_date\\\": \\\"YYYY-MM-DD\\\", \\\"end_date\\\": \\\"YYYY-MM-DD or null\\\" }\\n    ],\\n    \\\"refractory_relapsed_status\\\": \\\"relapsed/refractory/na/unknown\\\"\\n  },\\n  \\\"performance_status\\\": {\\n    \\\"ecog\\\": null,\\n    \\\"karnofsky\\\": null,\\n    \\\"weight_kg\\\": null,\\n    \\\"height_cm\\\": null,\\n    \\\"bmi\\\": null\\n  },\\n  \\\"labs\\\": {\\n    \\\"collection_date\\\": \\\"YYYY-MM-DD or null\\\",\\n    \\\"anc_10e9_per_L\\\": null,\\n    \\\"platelets_10e9_per_L\\\": null,\\n    \\\"hemoglobin_g_per_dL\\\": null,\\n    \\\"creatinine_mg_per_dL\\\": null,\\n    \\\"creatinine_clearance_mL_per_min\\\": null,\\n    \\\"ast_u_per_L\\\": null,\\n    \\\"alt_u_per_L\\\": null,\\n    \\\"total_bilirubin_mg_per_dL\\\": null,\\n    \\\"albumin_g_per_dL\\\": null,\\n    \\\"inr\\\": null,\\n    \\\"ptt_seconds\\\": null,\\n    \\\"qtc_ms\\\": null,\\n    \\\"qtc_method\\\": \\\"Fridericia/Bazett/unknown\\\",\\n    \\\"lvef_percent\\\": null,\\n    \\\"lvef_date\\\": \\\"YYYY-MM-DD or null\\\"\\n  },\\n  \\\"comorbidities\\\": {\\n    \\\"cns_status\\\": \\\"none/treated_stable/untreated/symptomatic/unknown\\\",\\n    \\\"on_cns_steroids_prednisone_mg_per_day\\\": null,\\n    \\\"seizure_controlled\\\": true,\\n    \\\"autoimmune_disease\\\": [\\n      { \\\"condition\\\": \\\"optional\\\", \\\"on_systemic_immunosuppression\\\": true }\\n    ],\\n    \\\"infections\\\": {\\n      \\\"hbv_status\\\": \\\"negative/positive/unknown\\\",\\n      \\\"hbv_dna_iu_per_mL\\\": null,\\n      \\\"hcv_status\\\": \\\"negative/positive/unknown\\\",\\n      \\\"hcv_rna_iu_per_mL\\\": null,\\n      \\\"hiv_status\\\": \\\"negative/positive/unknown\\\",\\n      \\\"cd4_count_per_uL\\\": null,\\n      \\\"on_antivirals\\\": true\\n    },\\n    \\\"ild_pneumonitis_history\\\": false,\\n    \\\"bleeding_risk\\\": \\\"none/low/high/unknown\\\",\\n    \\\"anticoagulation\\\": \\\"none/prophylactic/therapeutic\\\",\\n    \\\"cardiac_arrhythmia\\\": false,\\n    \\\"heart_failure_nyha\\\": \\\"I/II/III/IV/unknown/null\\\",\\n    \\\"uncontrolled_hypertension\\\": false,\\n    \\\"diabetes_uncontrolled\\\": false,\\n    \\\"pregnant\\\": false,\\n    \\\"lactating\\\": false,\\n    \\\"contraception_agreement\\\": true\\n  },\\n  \\\"timing\\\": {\\n    \\\"last_chemo_date\\\": \\\"YYYY-MM-DD or null\\\",\\n    \\\"last_io_date\\\": \\\"YYYY-MM-DD or null\\\",\\n    \\\"last_tki_date\\\": \\\"YYYY-MM-DD or null\\\",\\n    \\\"last_radiation_end_date\\\": \\\"YYYY-MM-DD or null\\\",\\n    \\\"last_major_surgery_date\\\": \\\"YYYY-MM-DD or null\\\",\\n    \\\"steroid_taper_end_date\\\": \\\"YYYY-MM-DD or null\\\"\\n  }\\n}\\n\\nStrongly recommended fields and accepted values\\n- measurable_disease_recist: \\\"yes\\\",\\\"no\\\",\\\"unknown\\\"\\n- sites_of_disease: array of strings; use anatomic sites\\n- Key lab thresholds (used for prescreen): ANC \u2265 1.5 \u00d7 10^9/L (some 1.0), platelets \u2265 100 \u00d7 10^9/L (some 75), Hgb \u2265 9 g/dL, CrCl \u2265 50\u201360 mL/min, AST/ALT \u2264 2.5 \u00d7 ULN (\u2264 5 \u00d7 ULN with liver mets), bilirubin \u2264 1.5 \u00d7 ULN (\u2264 3 \u00d7 ULN or per Gilbert\u2019s), albumin \u2265 3.0 g/dL, INR/PTT \u2264 1.5 \u00d7 ULN unless anticoagulated, QTc \u2264 470 ms (men often \u2264 450), LVEF \u2265 50% where relevant\\n- cns_status: \\\"none\\\",\\\"treated_stable\\\",\\\"untreated\\\",\\\"symptomatic\\\",\\\"unknown\\\"\\n- infections: HBV/HCV/HIV \\\"negative\\\",\\\"positive\\\",\\\"unknown\\\" with viral loads where available\\n- anticoagulation: \\\"none\\\",\\\"prophylactic\\\",\\\"therapeutic\\\"\\n- assay_source: \\\"tumor\\\",\\\"ctDNA\\\",\\\"other\\\",\\\"unknown\\\"\\n- pd_l1_scale: \\\"TPS\\\",\\\"CPS\\\",\\\"IC\\\",\\\"unknown\\\"\\n- msi_mmr: \\\"MSI-H\\\",\\\"MSS\\\",\\\"dMMR\\\",\\\"pMMR\\\",\\\"unknown\\\"\\n- variant_class: \\\"SNV\\\",\\\"indel\\\",\\\"fusion\\\",\\\"amp\\\",\\\"loh\\\",\\\"ihc\\\",\\\"fish\\\",\\\"other\\\",\\\"unknown\\\"\\n\\nUnknown/NA tolerances\\n- Mandatory fields listed above must be provided (age, patient_gender, primary_site, histology, stage, ecog, first_line_treatment, second_line_treatment, biomarkers). Where allowed, \\\"unknown\\\" is accepted but may reduce matches.\\n- All recommended fields may be null/\\\"unknown\\\" and we will apply conservative prescreening.\\n\\n3) Recency requirements and conflict resolution\\n- Labs: prefer within 14 days of intended screening; accept up to 28 days for prescreen.\\n- Imaging for disease assessment: within 6\u20138 weeks.\\n- QTc (ECG): within 30 days.\\n- Echocardiogram/MUGA (LVEF): within 3 months (6 months acceptable if clinically stable and protocol allows).\\n- Viral serologies (HBV/HCV/HIV): within 3 months (or per protocol).\\n- Biomarker report dates: prefer within 6\u201312 months; older allowed if clinically still representative and no intervening therapy likely to change status; fresh biopsy feasibility noted if older/discordant.\\n- ECOG/Karnofsky: assessed within 14 days.\\n\\nConflict handling\\n- We select the most recent value by default.\\n- If materially discordant values exist, we apply conservative logic for safety/eligibility (e.g., use the less favorable lab relative to thresholds), and retain both values with timestamps.\\n- Source quality tie-breakers: central lab > CLIA-certified local > research-only; for genomic calls, tissue-based negative overrides ctDNA negative for exclusionary markers; any validated positive supersedes older negatives unless a high-quality confirmatory negative exists post-therapy that plausibly abrogates the alteration (rare).\\n- For PD-L1/TMB/MSI, we prefer the assay most commonly accepted by protocols (e.g., 22C3 for PD-L1 TPS, validated NGS for TMB/MSI) and the most recent sample.\\n\\n4) Coding flexibility and staging preference\\n- Disease coding: can ingest ICD-O topography/morphology or free text; both are supported.\\n- Staging representation: preferred as structured fields stage_system + stage_value; we also accept a single composite string and will parse when possible. If both are provided and conflict, we prioritize structured fields and the most recent staging date if supplied.\\n- Tumor-type-specific fields: we do not require them explicitly, but we auto-infer relevance (e.g., EGFR/ALK/ROS1/MET/RET/NTRK/KRAS G12C for NSCLC; IDH1/2, 1p/19q for glioma; BRAF for melanoma/CRC; BRCA1/2, HRD for certain tumors). If provided, we will use them to expand or narrow matching accordingly.\\n\\nThis specification will allow us to construct a PatientStatus artifact fully compatible with ClinicalTrials\u2019 matching engine while meeting PatientStatus completeness requirements.\\n\\nback to you: Orchestrator.\"\n        }\n      ],\n      \"finish_reason\": \"stop\"\n    },\n    {\n      \"ai_model_id\": \"gpt-5\",\n      \"metadata\": {\n        \"logprobs\": null,\n        \"id\": \"chatcmpl-C9ZjNCtDO22JmBYAxomVC1rNbrt1W\",\n        \"created\": 1756398337,\n        \"system_fingerprint\": null,\n        \"usage\": {\n          \"prompt_tokens\": 16740,\n          \"completion_tokens\": 869\n        }\n      },\n      \"content_type\": \"message\",\n      \"role\": \"assistant\",\n      \"name\": \"Orchestrator\",\n      \"items\": [\n        {\n          \"metadata\": {},\n          \"content_type\": \"text\",\n          \"text\": \"I\u2019m the Orchestrator. We now have ClinicalTrials\u2019 and PatientStatus\u2019 schemas and requirements. Here\u2019s the plan and order to retrieve the eligible clinical trials for this patient:\\n\\n- Step 3: PatientHistory \u2014 After you provide the patient ID, I will instruct PatientHistory to pull the full chart and extract all fields needed for PatientStatus and ClinicalTrials (age, primary site, histology/subtype, stage and system, measurable disease status, sites of disease, biomarkers, treatment history with dates/lines/responses, ECOG, key labs, comorbidities/exclusions, concomitant meds, timing constraints, and logistics if available). Each agent must end with \u201cback to you: Orchestrator.\u201d\\n- Step 4: PatientStatus \u2014 I will provide those details to PatientStatus to construct a complete PatientStatus artifact aligned to the agreed JSON template and recency/format rules. Each agent must end with \u201cback to you: Orchestrator.\u201d\\n- Step 5: ClinicalTrials \u2014 I will pass the finalized PatientStatus to ClinicalTrials to generate the list of eligible trials, with optional geography/logistics filters. Each agent must end with \u201cback to you: Orchestrator.\u201d\\n\\nUser, can you provide me with the patient\u2019s ID so I can proceed with PatientHistory? Additionally, please share:\\n- Patient\u2019s location (city/state/country) and maximum travel radius (miles or km) for site filtering\\n- Any logistics preferences (tele-trial/home services acceptable: yes/no; language needs)\\n- Optional exclusions (e.g., unwilling to undergo biopsy, no blood transfusions, no phase 1)\\n\\nOnce you confirm and provide the ID, I will proceed to Step 3.\"\n        }\n      ],\n      \"finish_reason\": \"stop\"\n    }\n  ]\n}",
  "patient_id": null,
  "patient_data": [],
  "display_blob_urls": [],
  "display_clinical_trials": [],
  "output_data": [],
  "healthcare_agents": {}
}